Source: Bloom Health Partners
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Bloom Health Partners (BLMH) has closed the second tranche of its non-brokered private placement
  • Under the second tranche, the company issued 2,770,000 units at $0.20 per unit for gross proceeds of $554,000
  • The company has sold a total of 7,920,000 units for aggregate gross proceeds of $1,584,000 
  • Net proceeds will be used for ongoing working capital and corporate development
  • Bloom Health Partners Inc. is a global platform for healthcare security, diagnostic testing and occupational health-tech
  • Bloom Health Partners Inc. (BLMH) opened trading at $0.195 per share

Bloom Health Partners (BLMH) has closed the second tranche of its previously announced non-brokered private placement.

Under the second tranche, the company issued 2,770,000 units at $0.20 per unit for gross proceeds of $554,000.

Bloom Health has sold a total of 7,920,000 units for gross proceeds of C$1,584,000. 

Units consist of one common share and one-half of a transferable common share purchase warrant. Each whole warrant entitles the holder to acquire one additional common share for $0.30 until July 18, 2023.

Bloom Health Partners Inc. plans to use the net proceeds of the offering for ongoing working capital and corporate development.

In connection with closing the second tranche of the offering, the company paid $32,640 and issued 163,200 warrants to an arms-length party who assisted in introducing subscribers to the offering.

All securities issued are subject to a statutory hold until November 19, 2022.

Bloom Health Partners Inc. is a global platform for healthcare security, diagnostic testing and occupational health-tech.

Bloom Health Partners Inc. (BLMH) opened trading at $0.195 per share.

More From The Market Herald

" Update from Revive Therapeutics (CSE:RVV) on Phase 3 clinical trial for Bucillamine in COVID-19

Revive Therapeutics (RVV) has provided an update on the company’s U.S. Food & Drug Administration (FDA) Phase 3 clinical trial.

" Core One Labs (CSE:COOL) subsidiary Vocan successfully converts Psilocin precursor into Psilocybin

Core One Labs (CSE:COOL) subsidiary Vocan Biotechnologies has converted psilocin developed by Awakened Biosciences into viable API psilocybin.

" Small Pharma (TSXV:DMT) receives approval for DMT-assisted psychotherapy & SSRI drug study

Small Pharma (DMT) has received approval to initiate a drug interaction clinical trial in the U.K.

" Kovo HealthTech (TSXV:KOVO) sees 211 per cent year-over-year revenue growth

Kovo HealthTech Corp. (KOVO) reported its Q2 financial results for the period ending June 30, 2022.